AU2001244372B2 - Use of fulvestrant in the treatment of resistant breast cancer - Google Patents

Use of fulvestrant in the treatment of resistant breast cancer Download PDF

Info

Publication number
AU2001244372B2
AU2001244372B2 AU2001244372A AU2001244372A AU2001244372B2 AU 2001244372 B2 AU2001244372 B2 AU 2001244372B2 AU 2001244372 A AU2001244372 A AU 2001244372A AU 2001244372 A AU2001244372 A AU 2001244372A AU 2001244372 B2 AU2001244372 B2 AU 2001244372B2
Authority
AU
Australia
Prior art keywords
treatment
fulvestrant
breast cancer
lesions
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2001244372A
Other languages
English (en)
Other versions
AU2001244372A1 (en
Inventor
Beat Thurlimann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001244372(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2001244372A1 publication Critical patent/AU2001244372A1/en
Application granted granted Critical
Publication of AU2001244372B2 publication Critical patent/AU2001244372B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001244372A 2000-04-05 2001-04-02 Use of fulvestrant in the treatment of resistant breast cancer Expired AU2001244372B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0008172.9A GB0008172D0 (en) 2000-04-05 2000-04-05 Therapy
GB0008172.9 2000-04-05
PCT/GB2001/001500 WO2001074366A1 (en) 2000-04-05 2001-04-02 Use of fulvestrant in the treatment of resistant breast cancer

Publications (2)

Publication Number Publication Date
AU2001244372A1 AU2001244372A1 (en) 2002-01-03
AU2001244372B2 true AU2001244372B2 (en) 2006-02-16

Family

ID=9889101

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001244372A Expired AU2001244372B2 (en) 2000-04-05 2001-04-02 Use of fulvestrant in the treatment of resistant breast cancer
AU4437201A Pending AU4437201A (en) 2000-04-05 2001-04-02 Use of fulvestrant in the treatment of resistant breast cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU4437201A Pending AU4437201A (en) 2000-04-05 2001-04-02 Use of fulvestrant in the treatment of resistant breast cancer

Country Status (28)

Country Link
US (2) US20030158166A1 (enExample)
EP (2) EP1272195B1 (enExample)
JP (1) JP2003528919A (enExample)
KR (1) KR100757764B1 (enExample)
CN (1) CN1431905A (enExample)
AT (1) ATE306270T1 (enExample)
AU (2) AU2001244372B2 (enExample)
BR (1) BR0109789A (enExample)
CA (1) CA2403608A1 (enExample)
CH (1) CH1272195H1 (enExample)
CZ (1) CZ303096B6 (enExample)
DE (1) DE60113975T2 (enExample)
DK (1) DK1272195T3 (enExample)
EE (1) EE05026B1 (enExample)
ES (1) ES2248300T3 (enExample)
GB (1) GB0008172D0 (enExample)
HU (1) HU230064B1 (enExample)
IL (2) IL151932A0 (enExample)
IS (1) IS2869B (enExample)
MX (1) MXPA02009744A (enExample)
NO (1) NO329949B1 (enExample)
NZ (1) NZ539603A (enExample)
PL (1) PL201175B1 (enExample)
RU (1) RU2265438C2 (enExample)
SK (1) SK287779B6 (enExample)
UA (1) UA80388C2 (enExample)
WO (1) WO2001074366A1 (enExample)
ZA (1) ZA200207538B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0116620D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
CA2453111A1 (en) * 2001-07-07 2003-01-23 Alan Marshall Irving Pharmaceutical formulation for the intramuscular administration of fulvestrant
EP1623713A1 (en) * 2004-07-09 2006-02-08 Proskelia SAS Cominations of pure anti-estrogen with aromatase inhibitors
US8557863B2 (en) * 2005-09-27 2013-10-15 Robert Benson Aylor Suppression and prevention of tumors
WO2007062093A2 (en) * 2005-11-22 2007-05-31 Incyte Corporation Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
US20140161827A1 (en) * 2011-05-09 2014-06-12 University Of Virginia Patent Foundation Compositions and methods for treating cancer
CA2836831C (en) 2011-05-20 2015-06-02 Capital, Business Y Gestion De Finanzas S.L. Pharmaceutical composition
US20160375234A1 (en) * 2014-01-10 2016-12-29 Atossa Genetic Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions
US9421264B2 (en) * 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
SG11202002105WA (en) 2017-09-11 2020-04-29 Atossa Therapeutics Inc Methods for making and using endoxifen
WO2019224790A2 (en) * 2018-05-24 2019-11-28 Kashiv Biosciences, Llc Prodrugs of fulvestrant
JP7662204B2 (ja) 2019-07-03 2025-04-15 アトッサ・セラピューティクス・インコーポレイテッド エンドキシフェンの徐放性組成物
EP4110344A4 (en) * 2020-02-29 2024-03-13 The University Of Vermont Use of thyromimetics for the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Also Published As

Publication number Publication date
MXPA02009744A (es) 2004-02-26
HU230064B1 (hu) 2015-06-29
EE05026B1 (et) 2008-06-16
SK287779B6 (sk) 2011-09-05
DK1272195T3 (da) 2006-01-16
HUP0300339A2 (hu) 2003-06-28
PL201175B1 (pl) 2009-03-31
KR20030007501A (ko) 2003-01-23
WO2001074366A1 (en) 2001-10-11
CN1431905A (zh) 2003-07-23
AU4437201A (en) 2001-10-15
CZ303096B6 (cs) 2012-04-04
ZA200207538B (en) 2003-12-19
NZ539603A (en) 2008-02-29
SK14292002A3 (sk) 2003-08-05
DE60113975T2 (de) 2006-06-22
EP1586323A1 (en) 2005-10-19
JP2003528919A (ja) 2003-09-30
ATE306270T1 (de) 2005-10-15
RU2265438C2 (ru) 2005-12-10
ES2248300T3 (es) 2006-03-16
CH1272195H1 (enExample) 2019-10-15
NO20024735D0 (no) 2002-10-02
HK1051498A1 (en) 2003-08-08
EP1272195B1 (en) 2005-10-12
PL357936A1 (en) 2004-08-09
IL151932A0 (en) 2003-04-10
US20110183949A1 (en) 2011-07-28
NO329949B1 (no) 2011-01-31
EE200200574A (et) 2004-04-15
GB0008172D0 (en) 2000-05-24
DE60113975D1 (de) 2006-02-23
IS2869B (is) 2014-03-15
IL151932A (en) 2007-07-04
NO20024735L (no) 2002-11-27
CZ20023309A3 (cs) 2003-02-12
UA80388C2 (en) 2007-09-25
US20030158166A1 (en) 2003-08-21
EP1272195A1 (en) 2003-01-08
CA2403608A1 (en) 2001-10-11
KR100757764B1 (ko) 2007-09-12
IS6576A (is) 2002-10-01
HUP0300339A3 (en) 2009-01-28
BR0109789A (pt) 2003-01-21

Similar Documents

Publication Publication Date Title
US20110183949A1 (en) Use of Fulvestrant in the Treatment of Resistant Breast Cancer
US10034860B2 (en) Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
Ingle et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032
Bajetta et al. Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients
Mauriac et al. Fulvestrant (Faslodex™) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials
US20230310455A1 (en) Combination therapies for treatment of her2 cancer
AU2001244372A1 (en) Use of fulvestrant in the treatment of resistant breast cancer
Baumann et al. Estrogen receptor modulators and down regulators: Optimal use in postmenopausal women with breast cancer
JP2023504436A (ja) 乳がんの治療のための併用療法
RU2320339C2 (ru) Применение анастрозола для лечения женщин в постклимактерическом периоде, которые страдают ранним раком молочной железы
HRP20120084A2 (hr) FULVESTRANT U DOZI OD 500 mg ZA LIJEČENJE UZNAPREDOVALOG RAKA DOJKE
Beresford et al. Neoadjuvant endocrine therapy in breast cancer
KR20250163966A (ko) 리보시클립과 아로마타제 저해제를 병용하여 초기 유방암을 치료하는 방법
HK1081842A (en) Use of fulvestrant in the treatment of resistant breast cancer
HK1051498B (en) Use of fulvestrant in the treatment of resistant breast cancer
JP2007508265A (ja) 乳癌処置レジメン
Saeki et al. Evaluation of the safety and tolerability of oral TAS-108 in postmenopausal patients with metastatic breast cancer
KR20260006644A (ko) 유방암 치료에 사용하기 위한 카피바서티브, cdk4/6 억제제 및 풀베스트란트의 조합
Kothari et al. The Treatment of Advanced Breast Cancer: Focus on Fulvestrant.

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired